CardioVascular Dynamics wins U.S. patent approval for microcatheter.IRVINE, Calif.--(HealthWire)--Oct. 30, 1996--CardioVascular Dynamics Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CCVD CCVD Communauté de Communes du Val de Drôme CCVD Combustion Chemical Vapor Deposition ) on Wednesday announced that it has been notified by the U.S. Patent Office that a patent has been issued for the company's microcatheter technology for vascular access vascular access Clinical medicine The ability to enter the vascular system; the ease with which the vascular system can be entered for administering therapy or obtaining blood for testing and site-specific drug delivery. This patent, titled "Low Profile Infusion Catheter," covers the utilization of CVD's patented Multiple Microporous Membrane (M3) Technology to provide greater access to remote anatomical locations within the body and precise and accurate delivery of therapeutic solutions. CVD's M3 Technology also provides superior flexibility for maximum catheter performance in accessing difficult-to-reach locations in the body's anatomy. This patent includes the use of CVD's M3 Technology for coronary, peripheral vascular and neurovascular applications, as well as urological and site-specific delivery of chemotherapeutic drugs for cancer treatment. Compared with other patented microcatheter designs, M3 Technology enables CVD CVD Cardiovascular disease, see there to develop catheters with a multilumen design that are as small as conventional microcatheters that have only a single lumen design. The company believes that this multilumen concept provides catheters that can be constructed in either over-the-wire or rail design, providing the clinician clinician /cli·ni·cian/ (kli-nish´in) an expert clinical physician and teacher. cli·ni·cian n. with catheters that are multifunctional and more convenient to use than standard microcatheters. Commenting on the significance of this patent, CardioVascular Dynamics Chairman and Chief Executive Officer Michael Henson Michael Henson is a Cincinnati based teacher, activist and writer. Born April 14, 1947 in Sidney, Ohio he moved to Cincinnati to attend Xavier University where he majored in English. He later received a masters in English from University of Chicago. said: "This is the fundamental patent for microcatheter design, utilizing technology providing both over-the-wire and rail-design catheter technology. "In addition to providing additional patent protection for existing products, we expect to utilize this patent as a platform to design new catheter delivery systems for a number of clinical applications." CVD develops and markets site-specific drug delivery catheters, combined angioplasty-drug delivery, stent stent (stent) 1. a device or mold of a suitable material, used to hold a skin graft in place. 2. a slender rodlike or threadlike device used to provide support for tubular structures that are being anastomosed, or delivery systems and advanced therapeutic catheters. CONTACT: CVD, Irvine Heather Murray, 510/734-0464 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion